EGFR and colorectal carcinoma: During chemotherapy (e.g., 5-FU, oxaliplatin) or targeted therapy (e.g., anti-EGFR monoclonal antibodies), CRC cells often exhibit compensatory upregulation of HK2/LDHA or GLS pathways.